Last updated on February 2018

A Dose Frequency Optimization Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Brief description of study

The primary objective of this study is to show that PFS (progress-free survival) rate at 6 months and at 1 year after randomization, of Nivolumab 480 mg every 4 weeks is non-inferior to nivolumab 240 mg every 2 weeks in subjects with advanced/metastatic (Stage IIIb/IV) NSCLC (non-Sq and Sq).

Clinical Study Identifier: NCT02713867

Contact Investigators or Research Sites near you

Start Over

Enrique Perez, Site 0025

Texas Oncology, P.A.
Flower Mound, TX United States
  Connect »

Sharad Jain, Site 0016

Texas Oncology, P.A.
Denton, TX United States
  Connect »